For US Healthcare Professionals

Sotalol IV Logo

Somberg JC, Preston RA, Ranade V, Molnar J.  Developing a safe intravenous sotalol dosing regimen.  Am J Ther.  2010;17(4):365-372. doi:10.1097/MJT.0b013e3181ea3184

In this randomized, 2-treatment, 2-period crossover study, pharmacokinetic methods were used to study maximum serum concentrations in 18 patients in order to determine the optimal intravenous administration regimen.  Intravenous sotalol (75 mg) administered over 2.5 hours resulted in a significantly greater maximum concentration than oral sotalol (80 mg). https://pubmed.ncbi.nlm.nih.gov/20562595/

Highlights of Prescribing Information

Boxed Warning, Indications, and Important Safety Information

WARNING: LIFE THREATENING PROARRHYTHMIA

Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. (2.3)